by s2desi5_voyagertherapeutics | Dec 6, 2023 | Uncategorized |
– IND filing expected in mid-2025 – LEXINGTON, Mass. , Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it...
by s2desi5_voyagertherapeutics | Nov 6, 2023 | Uncategorized |
– GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing – – SOD1 ALS gene therapy program on track for development candidate selection by end of year – – Conference call...
by s2desi5_voyagertherapeutics | Oct 30, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating...
by s2desi5_voyagertherapeutics | Sep 25, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Sept. 25, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock , Jr.,...
by s2desi5_voyagertherapeutics | Sep 7, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Sept. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees...
